Coles starts FY23 with modest sales growth

Nick Sundich Nick Sundich, October 26, 2022

Coles (ASX:COL) reported its Q1 results for FY23 and these turned out positive for the company. The headline revenue growth figure was only 1.3%, but impressive in a time of high inflation and expenditure on hospitality higher than 12 months ago. 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

 

Coles records $9.9bn in sales

Coles’ revenue for the 13 weeks from 27 June to 25 September was $9.9bn. $8.8bn of this came from supermarkets, $836m from liquor and $284m from Express.

Liquor was down by 4.3% compared to the prior corresponding period which was inflated by lockdowns. But Express was 8.4% higher as people drove more than they could during lockdowns. Supermarkets was 1.6% higher than the prior corresponding period. 

 

Will the good times continue?

Coles’ results came in spite of the ‘Dropped & Locked’ initiative, which caps prices. In one sense, the results are positive.

But it is important to note, today’s results did not record mention bottom line figures, which would arguably give a clearer picture as to the impacts. Coles may not be as impacted by rising costs being a price setter, but it may be unable to avoid an impact altogether. Investors have sent shares down 1.8% this morning, arguably expecting a better result because supermarkets are the ultimate consumer staple category on the share market.

 

Coles (ASX:COL) share price chart (Graph: TradingView)

 

We think it will be interesting to compare its results to that of Woolworths, although its competitor reports on a different calendar so will not be updating shareholders until next month. 

 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

Blog Categories

Recent Posts

share buybacks

Share buybacks: Are they a good sign or a waste of money?

Share buybacks are a controversial topic amongst investors. Some say it is a waste of money, others will welcome it…

AFT Pharmaceuticals

AFT Pharmaceuticals (ASX:AFP): A gem of a dual-listed healthcare company

AFT Pharmaceuticals (ASX:AFP) may not spring to mind as the best company to have come out of New Zealand. Many…

Can Tabcorp’s nеw boss improve the stock’s dwindling odds?

Tabcorp (ASX: TAH) has had a dog of a year, with its share price dropping roughly 40% in the last…